Canadine

Canadine at a Glance

Canadine, better known in the pharmacology literature as tetrahydroberberine (THB), is an isoquinoline alkaloid of the tetrahydroprotoberberine class. It is the fully reduced (tetrahydro) form of berberine and a minor marker alkaloid of goldenseal root, where it sits alongside berberine and β-hydrastine ^{1Reference 1Scazzocchio F et al. · 2001In vitroAntibacterial activity of Hydrastis canadensis extract and its major isolated alkaloids — in vitroView study →}.

That single structural difference — a saturated ring in place of berberine’s flat, positively charged core — matters more than it sounds. It converts a quaternary cation with metabolic and gut-antimicrobial activity into a tertiary amine that crosses into the brain and engages dopamine receptors, the defining trait of its chemical family ^{2,4Reference 2Jin GZ et al. · 1986Tetrahydroprotoberberine — a new chemical type of antagonist of dopamine receptors — animal studyView study →Reference 4Gadhiya S et al. · 2016Tetrahydroprotoberberine alkaloids with dopamine and σ receptor affinity — medicinal chemistry / SARView study →}. Canadine is therefore best understood not as “a kind of berberine” but as a member of the CNS-active tetrahydroprotoberberine group — the same class as l-tetrahydropalmatine and l-stepholidine.

The honest evidence posture: canadine itself is data-thin. There are no human trials. What exists is a small preclinical literature — some on canadine directly (its contribution to goldenseal’s antibacterial and airway effects) and more on the tetrahydroprotoberberine scaffold as a whole ^{1,2,3,5Reference 1Scazzocchio F et al. · 2001In vitroAntibacterial activity of Hydrastis canadensis extract and its major isolated alkaloids — in vitroView study →Reference 2Jin GZ et al. · 1986Tetrahydroprotoberberine — a new chemical type of antagonist of dopamine receptors — animal studyView study →Reference 3Wu C et al. · 2010In vitroTetrahydroberberine blocks ATP-sensitive potassium channels in dopamine neurons acutely-dissociated from rat substantia nigra pars compacta — in vitro electrophysiologyView study →Reference 5Abdel-Haq H et al. · 2000Relaxant effects of Hydrastis canadensis L. and its major alkaloids on guinea pig isolated trachea — ex vivoView study →}.

Canadine as Reduced Berberine (Tetrahydroberberine)

Canadine and berberine share the same carbon skeleton but differ at one ring, and the difference reorganises the pharmacology.

Berberine is a quaternary protoberberine — permanently positively charged, flat, and poorly absorbed; its activity is dominated by gut and hepatic effects (glucose and lipid metabolism, luminal antimicrobial action) rather than by the central nervous system.

Canadine is berberine with that ring reduced — a tetrahydroprotoberberine, hence “tetrahydroberberine.” Reduction removes the permanent charge and yields a tertiary amine that is more lipophilic, better able to enter the brain, and — like the rest of its class — active at dopamine receptors ^{2,4Reference 2Jin GZ et al. · 1986Tetrahydroprotoberberine — a new chemical type of antagonist of dopamine receptors — animal studyView study →Reference 4Gadhiya S et al. · 2016Tetrahydroprotoberberine alkaloids with dopamine and σ receptor affinity — medicinal chemistry / SARView study →}. Tetrahydroprotoberberines behave broadly as dopamine-receptor antagonists, an activity the parent quaternary berberine essentially does not share ^{2Reference 2Jin GZ et al. · 1986Tetrahydroprotoberberine — a new chemical type of antagonist of dopamine receptors — animal studyView study →}.

The two are also linked biochemically in the plant. Canadine — as (S)-canadine — is the immediate biosynthetic precursor to berberine: a single oxidase step, (S)-canadine oxidase / tetrahydroberberine oxidase, dehydrogenates canadine to berberine ^{6,7Reference 6Galneder E et al. · 1988Alternative final steps in berberine biosynthesis in Coptis japonica cell cultures — (S)-canadine oxidase — plant biochemistryView study →Reference 7Okada N et al. · 1989Isolation, sequence, and bacterial expression of a cDNA for (S)-tetrahydroberberine oxidase from cultured berberine-producing Coptis japonica cells — plant enzymologyView study →}. Canadine is, quite literally, one enzyme short of berberine.

The practical reading: do not transfer berberine’s metabolic clinical data to canadine, and do not transfer canadine’s CNS pharmacology to berberine. They are different molecules with different targets that happen to sit next to each other on a biosynthetic pathway.

What It's Used For

The evidence is preclinical throughout. The most substantive theme is the CNS / dopamine-receptor pharmacology of the tetrahydroprotoberberine class, though much of that work is on canadine’s relatives rather than canadine as consumed; the direct canadine data are the goldenseal antibacterial and airway-relaxant contributions.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume, tempered for isolate-vs-plant match. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Each application links down to its write-up. Canadine scores low across the board — everything here is preclinical.

01CNS & Dopamine-Receptor ActivityPromising46%Animal + in-vitro on the tetrahydroprotoberberine class; much on relatives, not canadine directly ^{2,3,4Reference 2Jin GZ et al. · 1986Tetrahydroprotoberberine — a new chemical type of antagonist of dopamine receptors — animal studyView study →Reference 3Wu C et al. · 2010In vitroTetrahydroberberine blocks ATP-sensitive potassium channels in dopamine neurons acutely-dissociated from rat substantia nigra pars compacta — in vitro electrophysiologyView study →Reference 4Gadhiya S et al. · 2016Tetrahydroprotoberberine alkaloids with dopamine and σ receptor affinity — medicinal chemistry / SARView study →}

02Antibacterial ContributorShaky36%Isolated goldenseal alkaloids vs 6 strains; canadine a contributor, not the driver ^{1Reference 1Scazzocchio F et al. · 2001In vitroAntibacterial activity of Hydrastis canadensis extract and its major isolated alkaloids — in vitroView study →}

03Airway Smooth-Muscle RelaxationShaky30%Single ex-vivo guinea-pig trachea study ^{5Reference 5Abdel-Haq H et al. · 2000Relaxant effects of Hydrastis canadensis L. and its major alkaloids on guinea pig isolated trachea — ex vivoView study →}

Mechanisms

Pharmacokinetics

Essentially unstudied for canadine in humans. No oral bioavailability figure, plasma half-life or metabolite map has been established here. Two structural inferences are worth stating and no more: unlike quaternary berberine (oral bioavailability <1%, gut-confined), canadine is a lipophilic tertiary amine, which is consistent with better membrane penetration and the CNS activity its class shows — but this is inference from structure and class behaviour, not measured human data. Its metabolic fate (including any re-oxidation toward berberine-type products) has not been characterised here.

Clinical Trials

None. No registered or published human clinical trials of canadine (tetrahydroberberine) as an isolated agent were identified.

Last checked: July 2026.

Isolate vs. Plant Studies

All of canadine’s evidence is on the isolated molecule or on isolated members of its chemical class — there is no whole-plant trial that isolates a canadine effect. The two direct canadine findings (antibacterial, tracheal relaxation) both come from studies that purified goldenseal alkaloids and tested them individually ^{1,5Reference 1Scazzocchio F et al. · 2001In vitroAntibacterial activity of Hydrastis canadensis extract and its major isolated alkaloids — in vitroView study →Reference 5Abdel-Haq H et al. · 2000Relaxant effects of Hydrastis canadensis L. and its major alkaloids on guinea pig isolated trachea — ex vivoView study →}, which is the right design but leaves canadine as a minor voice in a root dominated by berberine and hydrastine. The CNS pharmacology, meanwhile, leans heavily on canadine’s relatives (l-tetrahydropalmatine, l-stepholidine) ^{2,4Reference 2Jin GZ et al. · 1986Tetrahydroprotoberberine — a new chemical type of antagonist of dopamine receptors — animal studyView study →Reference 4Gadhiya S et al. · 2016Tetrahydroprotoberberine alkaloids with dopamine and σ receptor affinity — medicinal chemistry / SARView study →}. The transferability caveat cuts both ways: goldenseal’s traditional effects should not be attributed to canadine, and the dopamine-antagonist behaviour of the broader tetrahydroprotoberberine class should not be assumed to occur at the trace canadine levels in a goldenseal preparation.

Its Role in Plants

Canadine is a benzylisoquinoline alkaloid built, like the rest of its family, from the branch-point intermediate (S)-reticuline. Its plant role is best described by its position on the pathway: (S)-canadine is the direct precursor to berberine. In Coptis (and in goldenseal’s shared chemistry), the methylenedioxy bridge is formed on the tetrahydroprotoberberine skeleton to give (S)-canadine, which is then dehydrogenated to berberine by (S)-canadine oxidase (tetrahydroberberine oxidase) — an oxidase characterised and cloned from berberine-producing Coptis japonica cell cultures ^{6,7Reference 6Galneder E et al. · 1988Alternative final steps in berberine biosynthesis in Coptis japonica cell cultures — (S)-canadine oxidase — plant biochemistryView study →Reference 7Okada N et al. · 1989Isolation, sequence, and bacterial expression of a cDNA for (S)-tetrahydroberberine oxidase from cultured berberine-producing Coptis japonica cells — plant enzymologyView study →}. Canadine thus accumulates as a reduced intermediate that plants convert onward to the quaternary, brightly pigmented berberine; where oxidation is incomplete, canadine persists as a minor end-product alkaloid.

Prevalence in Nature

Canadine occurs chiefly in the root and rhizome of goldenseal (Hydrastis canadensis), where it is a minor alkaloid — present alongside the far more abundant berberine and β-hydrastine, and typically on the order of ~1% or less of dry root ^{1Reference 1Scazzocchio F et al. · 2001In vitroAntibacterial activity of Hydrastis canadensis extract and its major isolated alkaloids — in vitroView study →}. It is also reported in Corydalis species and scattered across other alkaloid-rich Papaveraceae and Ranunculaceae, the same families that make berberine ^{8Reference 8Neag MA et al. · 2018ReviewBerberine: botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders — reviewView study →}. As in berberine, it concentrates in underground organs (roots, rhizomes) rather than leaves.

Major Natural Sources

Source	Botanical	Part	Notes
Goldenseal	Hydrastis canadensis	Root / rhizome	Principal source; minor vs berberine & hydrastine 1Reference 1Scazzocchio F et al. · 2001In vitroAntibacterial activity of Hydrastis canadensis extract and its major isolated alkaloids — in vitroView study →
Corydalis	Corydalis spp.	Tuber / root	Tetrahydroprotoberberine-rich genus
Other Papaveraceae / Ranunculaceae	various	Root	Trace, reported qualitatively 8Reference 8Neag MA et al. · 2018ReviewBerberine: botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders — reviewView study →

Discovery & Synthesis

Canadine was isolated from goldenseal (Hydrastis canadensis), and the alkaloid takes its name directly from the plant (and, through it, from Canada); the older synonym xanthopuccine likewise references the root’s yellow pigment. In the chemistry literature the compound is more often called tetrahydroberberine, a name that states its relationship to berberine outright — it is berberine with the central ring reduced. Because it is the direct biosynthetic precursor to berberine, canadine can also be obtained by partial reduction of berberine, a route long used to prepare the tetrahydro compound for study. There is no commercial demand for isolated canadine; it is prepared in small quantities for research (by extraction or by reduction of the cheap, abundant berberine) rather than manufactured at scale.

Patents: not yet researched (future patent-loop pass).

Toxicity & Safety

Canadine’s safety is essentially unstudied as an isolated compound, and this is the honest headline — an absence of data, not evidence of safety. Human dietary exposure is small and indirect (a minor alkaloid of goldenseal root), which is reassuring at the level of ordinary herbal use, but the molecule’s own pharmacology carries a plausible flag: as a brain-penetrant dopamine-receptor antagonist, its chemical class produces sedation and neuroleptic-like effects in animals ^{2Reference 2Jin GZ et al. · 1986Tetrahydroprotoberberine — a new chemical type of antagonist of dopamine receptors — animal studyView study →}, so pharmacological doses would not be expected to be inert. No isolated-compound toxicology, carcinogenicity, or reproductive data were located.

Safety at a Glance

✅ Low / no toxicity

• Minor, indirect dietary exposure. Canadine is consumed only as a trace goldenseal alkaloid, not as a stand-alone supplement.
• Brain-penetrant dopamine antagonist (class effect). The tetrahydroprotoberberine family is sedative/neuroleptic-like in animals; pharmacological doses would not be inert ^{2,4Reference 2Jin GZ et al. · 1986Tetrahydroprotoberberine — a new chemical type of antagonist of dopamine receptors — animal studyView study →Reference 4Gadhiya S et al. · 2016Tetrahydroprotoberberine alkaloids with dopamine and σ receptor affinity — medicinal chemistry / SARView study →}.
• Safety essentially unstudied. No human data, no isolated-compound toxicology, no interaction or pregnancy assessment for canadine specifically — treat silence as unknown, not safe.

Note on scope: drug-interaction and pregnancy/lactation risk were not assessed for canadine here — those decisions belong to the whole-herb goldenseal monograph, where intake is actually decided, and where goldenseal’s better-characterised alkaloids (berberine’s kernicterus and CYP-inhibition concerns, hydrastine’s CYP3A4 inhibition) drive the verdict.

Dosage

There is no established or studied human dose for canadine. It has never been used as a stand-alone medicine. The figures in the pharmacology sections above are research concentrations in cells and isolated tissues (e.g. a tracheal EC50 near 11.9 µg/mL ^{5Reference 5Abdel-Haq H et al. · 2000Relaxant effects of Hydrastis canadensis L. and its major alkaloids on guinea pig isolated trachea — ex vivoView study →}), not doses given to people. Human exposure occurs only as a minor alkaloid within goldenseal preparations, where the dose “of canadine” is whatever trace amount the root and preparation happen to contain. Any figure here would be a research concentration and is not a personal recommendation.

References

1. Scazzocchio F, Cometa MF, Tomassini L, Palmery M. (2001). Antibacterial activity of Hydrastis canadensis extract and its major isolated alkaloids — in vitro. Planta Medica, 67(6), 561–564. https://pubmed.ncbi.nlm.nih.gov/11509983/
2. Jin GZ, Wang XL, Shi WX. (1986). Tetrahydroprotoberberine — a new chemical type of antagonist of dopamine receptors — animal study. Scientia Sinica (Series B), 29(5), 527–534. https://pubmed.ncbi.nlm.nih.gov/2880397/
3. Wu C, Yang K, Liu Q, Wakui M, Jin GZ, Zhen X, Wu J. (2010). Tetrahydroberberine blocks ATP-sensitive potassium channels in dopamine neurons acutely-dissociated from rat substantia nigra pars compacta — in vitro electrophysiology. Neuropharmacology, 59(7–8), 567–572. https://pubmed.ncbi.nlm.nih.gov/20804776/
4. Gadhiya S, Madapa S, Kurtzman T, Alberts IL, Ramsey S, Pillarsetty NK, et al. (2016). Tetrahydroprotoberberine alkaloids with dopamine and σ receptor affinity — medicinal chemistry / SAR. Bioorganic & Medicinal Chemistry, 24(9), 2060–2071. https://pubmed.ncbi.nlm.nih.gov/27032890/
5. Abdel-Haq H, Cometa MF, Palmery M, Leone MG, Silvestrini B, Saso L. (2000). Relaxant effects of Hydrastis canadensis L. and its major alkaloids on guinea pig isolated trachea — ex vivo. Pharmacology & Toxicology, 87(5), 218–222. https://pubmed.ncbi.nlm.nih.gov/11129501/
6. Galneder E, Rueffer M, Wanner G, Tabata M, Zenk MH. (1988). Alternative final steps in berberine biosynthesis in Coptis japonica cell cultures — (S)-canadine oxidase — plant biochemistry. Plant Cell Reports, 7(1), 1–4. https://pubmed.ncbi.nlm.nih.gov/24241402/
7. Okada N, Koizumi N, Tanaka T, Ohkubo H, Nakanishi S, Yamada Y. (1989). Isolation, sequence, and bacterial expression of a cDNA for (S)-tetrahydroberberine oxidase from cultured berberine-producing Coptis japonica cells — plant enzymology. Proceedings of the National Academy of Sciences USA, 86(2), 534–538. https://pubmed.ncbi.nlm.nih.gov/2463630/
8. Neag MA, Mocan A, Echeverría J, Pop RM, Bocsan CI, Crişan G, Buzoianu AD. (2018). Berberine: botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders — review. Frontiers in Pharmacology, 9, 557. https://pubmed.ncbi.nlm.nih.gov/30186157/

View all 8 references▾